INS and cancer: Previous studies have shown that the Insulin secretion pathway is abnormally expressed in certain cancer types, and this abnormality may lead to drug resistance.[27] Other top positive pathways, such as the ErbB signaling pathway and Estrogen signaling pathway, have also been proven to be associated with resistance mechanisms in previous research.[28, 29] These pathways exhibit higher activity in the insensitive group (Figure S13A–C, Supporting Information).